-
Management of comorbidities in bleeding disorders
Three decades of people with hemophilia unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, has again...
-
Substitution therapy
Hemlibra (emicizumab) is indicated in Canada for hemophilia A patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the...
-
Inhibitors – think differently
The development of inhibitory antibodies to therapeutic FVIII in up to 40% of severe hemophilia A (HA) patients is a major complication in the treatment...
-
The WFH Gene Therapy and Bleeding Disorders Registries
WFH Gene Therapy Registry, presented by Dr. Barbara Konkle For many years gene therapy has been in the future – but now, for an increasing...
-
Critical need for harmonized post-marketing surveillance in gene therapy
With regulatory approval of the first gene therapy for clinical use outside of clinical trials anticipated in mid-2020, there is an urgent need to collect...